1. Economic Evaluation of Pravastatin for Primary Prevention of Coronary Artery Disease Based on Risk Prediction from JALS-ECC in Japan 
Yoshie Onishi, MS, MPH, Shiro Hinotsu, MD, PhD, Yoko M. Nakao, MD, Hisashi Urushihara, DrPH, Koji Kawakami, MD, PhD 
Value in Health Regional Issues 
Volume 2, Issue 1, Pages 5-12 (May 2013)
DOI: /j.vhri
Copyright © 2013 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

2. Fig. 1
Structure of the Markov transition model for cost-effectiveness of pravastatin 10 mg/day.
Value in Health Regional Issues 2013 2, 5-12DOI: ( /j.vhri )
Copyright © 2013 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

3. Fig. 2
Cost-effectiveness acceptability curve for therapy with pravastatin 10 mg/day.
Value in Health Regional Issues 2013 2, 5-12DOI: ( /j.vhri )
Copyright © 2013 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions